• 2016

Company Description

Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells.

Repare has developed and deployed a proprietary, high-throughput, genomic synthetic lethal screening platform that harnesses the precision and power of CRISPR/Cas9 genome editing, high-resolution protein crystallography and computational biology, and the unprecedented ability to exploit DNA Damage Repair (DDR) defects found across virtually all cancers.